0000950123-24-005471.txt : 20240515 0000950123-24-005471.hdr.sgml : 20240515 20240515130003 ACCESSION NUMBER: 0000950123-24-005471 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240515 DATE AS OF CHANGE: 20240515 EFFECTIVENESS DATE: 20240515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Bain Capital Life Sciences Investors, LLC CENTRAL INDEX KEY: 0001703031 ORGANIZATION NAME: IRS NUMBER: 813996001 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-18477 FILM NUMBER: 24948843 BUSINESS ADDRESS: STREET 1: 200 CLARENDON STREET CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 6175162878 MAIL ADDRESS: STREET 1: 200 CLARENDON STREET CITY: BOSTON STATE: MA ZIP: 02116 13F-HR 1 primary_doc.xml X0202 13F-HR LIVE 0001703031 XXXXXXXX 03-31-2024 03-31-2024 false Bain Capital Life Sciences Investors, LLC

200 Clarendon Street Boston MA 02116

13F HOLDINGS REPORT 028-18477 Y Bain Capital Life Sciences Investors, LLC is (i) the general partner of Bain Capital Life Sciences Partners, LP, which is the general partner of Bain Capital Life Sciences Fund, L.P., (ii) the general partner of BC SW, LP, (iii) the manager of Bain Capital Life Sciences Investors II, LLC, which is the general partner of Bain Capital Life Sciences Fund II, L.P., which is the manager of BCLS II Investco (GP), LLC, which is the general partner of BCLS II Investco, LP, and (iv) the manager of Bain Capital Life Sciences III General Partner, LLC, which is the general partner of Bain Capital Life Sciences Fund III, L.P., which is the sole member of Bain Capital Life Sciences Opportunities III GP, LLC, which is the general partner of Bain Capital Life Sciences Opportunities III, LP. The shares of Annexon Inc. ("ANNX") include an aggregate of 3,514,418 shares of ANNX common stock issuable upon conversion of warrants and pre-funded warrants. As of 3/31/24, Bain Capital Life Sciences Fund, L.P., BCIP Life Sciences Associates, LP and BCLS I Investco, LP held 4,935,330 shares of ANNX common stock. The shares of Savara Inc. ("SVRA") are as reported on Amendment No. 3 to the Schedule 13D filed by Bain Capital Life Sciences Fund II, L.P., BCIP Life Sciences Associates, LP and BCLS II Investco, LP on 4/12/24 and reflect the exercise of securities held by such persons for SVRA common stock, after giving effect to provisions that prevent exercise if such persons would beneficially own more than 9.99% of the SVRA common stock following such exercise. As of 3/31/24, such persons held 6,913,208 shares of SVRA common stock. The shares of Syros Pharmaceuticals, Inc. ("SYRS") are as reported on Amendment No. 3 to the Schedule 13G filed by Bain Capital Life Sciences Fund II, L.P., BCIP Life Sciences Associates, LP and BCLS II Equity Opportunities, LP on 2/13/24 and reflect the exercise of securities held by such persons for SYRS common stock, after giving effect to provisions that prevent exercise if such persons would beneficially own more than 9.99% of the SYRS common stock following such exercise. As of 3/31/24, such persons held 1,230,857 shares of SYRS common stock. The shares of X4 Pharmaceuticals, Inc. ("XFOR") reflect the exercise of securities held by Bain Capital Life Sciences Fund, L.P., Bain Capital Life Sciences Fund II, L.P., BCIP Life Sciences Associates, LP, BCLS II Investco, LP and BCLS I Investco, LP for XFOR common stock, after giving effect to provisions the prevent exercise if such persons would beneficially own more than 9.99% of the XFOR common stock following such exercise. As of 3/31/24, such persons held 14,879,809 shares of XFOR common stock. The shares of Dianthus Therapeutics, Inc. ("DNTH") are as reported on the Schedule 13G filed by BCLS Fund III Investments, LP on 2/2/24 and reflect the exercise of securities held by such person for DNTH common stock, after giving effect to provisions that prevent exercise if such person would beneficially own more than 9.99% of the DNTH common stock following such exercise. As of 3/31/24, such person held 2,360,059 shares of DNTH Common Stock. Adam Koppel 617-516-2000 /s/ Adam Koppel Boston MA 05-15-2024 11 26 1244287799 false 1 28-18476 Bain Capital Life Sciences Partners, LP 2 28-18478 Bain Capital Life Sciences Fund, L.P. 3 28-20270 BC SW, LP 4 28-20816 Bain Capital Life Sciences Investors II, LLC 5 28-20814 Bain Capital Life Sciences Fund II, L.P. 6 28-22976 BCLS II Investco (GP), LLC 7 28-22978 BCLS II Investco, LP 8 28-22975 Bain Capital Life Sciences III General Partner, LLC 9 28-22979 Bain Capital Life Sciences Fund III, L.P. 10 28-22968 Bain Capital Life Sciences Opportunities III GP, LLC 11 28-22966 Bain Capital Life Sciences Opportunities III, LP INFORMATION TABLE 2 32559.xml INFORMATION TABLE FOR FORM 13F ACLARIS THERAPEUTICS INC COM 00461U105 3720000 3000000 SH SOLE 3000000 0 0 ANNEXON INC COM 03589W102 62402432 8703268 SH SOLE 8703268 0 0 ARCUTIS BIOTHERAPEUTICS INC COM 03969K108 19935818 2011687 SH SOLE 2011687 0 0 ATEA PHARMACEUTICALS INC COM 04683R106 10041978 2485638 SH SOLE 2485638 0 0 C4 THERAPEUTICS INC COM STK 12529R107 9331856 1142210 SH SOLE 1142210 0 0 CABALETTA BIO INC COM 12674W109 27592230 1617364 SH SOLE 1617364 0 0 DIANTHUS THERAPEUTICS INC COM 252828108 89760840 2992028 SH SOLE 2992028 0 0 DISC MEDICINE INC COM 254604101 82009681 1317213 SH SOLE 1317213 0 0 INVIVYD INC COM 00534A102 7990202 1799595 SH SOLE 1799595 0 0 KYVERNA THERAPEUTICS INC COM 501976104 78590481 3163868 SH SOLE 3163868 0 0 MADRIGAL PHARMACEUTICALS INC COM 558868105 52605545 196995 SH SOLE 196995 0 0 MARINUS PHARMACEUTICALS INC COM NEW 56854Q200 12596155 1393380 SH SOLE 1393380 0 0 MERSANA THERAPEUTICS INC COM 59045L106 38813255 8663673 SH SOLE 8663673 0 0 NAUTILUS BIOTECHNOLOGY INC COM 63909J108 5880000 2000000 SH SOLE 2000000 0 0 NEWAMSTERDAM PHARMA COMPANY ORDINARY SHARES N62509109 247708042 10473913 SH SOLE 10473913 0 0 NEWAMSTERDAM PHARMA COMPANY *W EXP 99/99/999 N62509117 1104000 100000 SH SOLE 100000 0 0 NURIX THERAPEUTICS INC COM 67080M103 16646236 1132397 SH SOLE 1132397 0 0 NUVALENT INC COM 670703107 202537779 2697267 SH SOLE 2697267 0 0 PHARVARIS N V COM N69605108 76341135 3303381 SH SOLE 3303381 0 0 RAPID MICRO BIOSYSTEMS INC CLASS A COM 75340L104 8181523 8434560 SH SOLE 8434560 0 0 SAVARA INC COM 805111101 72535976 14565457 SH SOLE 14565457 0 0 SOLID BIOSCIENCES INC COM NEW 83422E204 53740632 4034582 SH SOLE 4034582 0 0 SYROS PHARMACEUTICALS INC COM NEW 87184Q206 14711473 2749808 SH SOLE 2749808 0 0 TANGO THERAPEUTICS INC COM 87583X109 22967744 2892663 SH SOLE 2892663 0 0 X4 PHARMACEUTICALS INC COM 98420X103 23512940 16915784 SH SOLE 16915784 0 0 XILIO THERAPEUTICS INC COM 98422T100 3029846 2805413 SH SOLE 2805413 0 0